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Abstract In the present study we have examined the levels and 
phosphorylation state of the insulin receptor and insulin receptor 
substrate 1 0RS-I)  as well as the association between IRS-1 and 
phosphatidylinositol 3-kinase (PI 3-kinase) in the liver and muscle 
of rats treated with glucagon. There was a decrease in the insulin- 
stimulated receptor and IRS-1 pbosphorylation levels which was 
paralleled by a reduced association between IRS-1 and PI 3- 
kinase in vivo in the liver and muscle of glucagon-treated rats. 
These observations suggest that glucagon, probably acting 
through cAMP, may impair insulin signaling in the three early 
steps in insulin action after binding. 
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1. Introduction 
Insulin plays a central role in the regulation of blood glucose 
levels and acts in a coordinated fashion to stimulate protein and 
lipid metabolism by modifying the activity of  various enzymes 
and/or transport proteins. Although the exact molecular events 
linking the insulin receptor tyrosine kinase to its final cellular 
actions remain poorly understood, several of the early steps in 
the insulin action cascade have been defined at a molecular 
level. First, insulin stimulates the tyrosine phosphorylation of 
cytoplasmic proteins with a relative molecular mass between 
165 and 185 kDa, termed pp185 [1-3]. Insulin receptor sub- 
strate 1 (IRS-1) is a component of pp185 and is a substrate of 
insulin, insulin-like growth factor-1, and interleukin-4 receptors 
[1--4]. Following its phosphorylation, IRS-1 can associate with 
proteins containing Src homology 2 (SH2) domains through 
specific tyrosyl phosphorylation sites [5,6]. This association 
leads to activation of the enzyme phosphatidylinositol 3-kinase 
(PI 3-kinase) [7,8]. Thus, the insulin receptor, IRS-1 and PI 
3-kinase represent hree of the earliest steps in insulin action, 
each of which can be demonstrated in vivo in two of the main 
target tissues for the metabolic actions of insulin, namely liver 
and muscle [8]. Recently, we demonstrated alterations in these 
early steps of insulin action in liver and muscle of animal mod- 
els of insulin resistance [9-11] 
It has long been known that an increase in intracellular cyclic 
AMP levels induce insulin resistance at both receptor and post- 
receptor levels [12-15]. Using purified receptors and artificial 
substrates in vitro, decreased insulin receptor phosphorylation 
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and kinase activity have been reported as a consequence of 
increased cAMP and cAMP kinase [14,15], although such a 
change is not always observed [16]. In the present study, we 
have examined the phosphorylation state of the insulin receptor 
and IRS-I as well as the association of the latter with PI 3- 
kinase in the liver and muscle of glucagon-treated rats stimu- 
lated with insulin in vivo. 
2. Materials and methods 
2.1. Materials" 
The reagents for sodium dodecyl sulfate-polyacrylamide gel lectro- 
phoresis (SDS-PAGE) and immunoblotting were from Bio-Rad 
(Richmond, CA). N-2-Hydroxyethyl-piperarine-N-2 ethanesulfonic 
acid (HEPES), phenylmethylsulfonylfluoride (PMSF), aprotinin, 
dithiothreitol (DTT), Triton X-100, Tween 20, glycerol, glucagon and 
bovine serum albumin (BSA, fraction V) were from Sigma Chemical 
Co. (St. Louis, MO). Protein A-Sepharose 6MB was from Pharmacia 
(Uppsala, Sweden), [lZSI]protein A was from ICN Biomedicals (Costa 
Mesa, CA), and nitrocellullose paper (BA85, 0.2 mm) was from 
Schleicher & Schuell. Sodium amobarbital (Amytal) and human recom- 
binant insulin (Humulin R) were from Eli Lilly. Monoclonal an- 
tiphosphotyrosine antibody and anti-rat-PI 3-kinase antiserum were 
from UBI (Lake Placid, NY). Anti-insulin receptor antibody and anti- 
IRS-1 antibodies were raised in rabbits using a synthetic peptide de- 
rived from the amino acid sequence of the C-terminus of the proteins, 
as previously described [11], and were kindly provided by Dr. C.R. 
Kahn and M.F. White (Joslin Diabetes Center, Boston, MA). 
2.2. Methods' 
2.2.1. Animals and tissue extracts. Male rats (130-180 g) were 
allowed access to standard rodent chow and water ad libitum. The 
animals were studied after 12 h of fasting. The studies were performed 
in parallel for the control and treated rats in each pair, 
Rats were anesthetized with sodium amobarbital (15 mg/kg body 
weight, i.p.) and used in experiments a soon as anesthesia was assured 
by loss of pedal and corneal reflexes. Initially rats were injected i.p. with 
glucagon 100/tg/100 grat or an equal volume of saline (control group). 
Five minutes later, the abdominal cavity was opened, the portal vein 
exposed, and 0.5 ml of normal saline (0.9% NaCI) with or without 10 -5 
M insulin was injected. At 30 s, the livers were removed, minced 
coarsely and homogenized immediately in approximately 10 volumes 
of solubilization buffer A in a water bath maintained at 100°C with a 
Polytron PTA 20S generator (Brinkmann Instruments model PT 10/35) 
operated at maximum speed (setting 10) for 30 s. The solubilization 
buffer A was composed of 1% SDS, 50 mM HEPES (pH 7.4), 100 mM 
sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, and 
10 mM sodium vanadate. The homogenate was boiled for 10 min and 
then cooled in an ice bath for 40 min. 
Approximately 90 s after insulin injection, hindlimb muscles were 
excised and then homogenized with a Polytron in 6 volumes of homog- 
enization buffer A at 100°C. The extracts were centrifuged at 15,000 
rpm at 4°C in a Beckman 70.1 Ti rotor for 60 min to remove insoluble 
material, and the supernatant was used as a sample. In some experi- 
ments, the tissues were extracted at 4°C with homogenization buffer B 
(same as buffer A except hat 1% Triton X-100 replaced 1% SDS and 
2 mM PMSF and 0.1 nag aprotinin/ml were added), and after centrifu- 
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Fig. 1. Insulin-stimulated tyrosine phosphorylation in the intact liver of glucagon-treated rats. Rats were anesthetized, and the abdominal wall incised 
to expose the viscera. Normal saline (lanes 1,3) or 10 -5 M insulin (lanes 2,4) was infused into the portal vein as a bolus injection and 30 s later the 
livers were excised and homogenized in extraction buffer A at 100°C as described in section 2.2. After centrifugation, aliquots containing the same 
amounts of protein were resolved on 6% SDS-polyacrylamide g ls, transferred to nitrocellulose filters, and detected with anti-phosphotyrosine 
antibody (panel A), anti-IRS-1 antibody, or anti-insulin receptor antibody, and [~25I]protein A and subjected to autoradiography. Panels B and C 
show the immunoblotting of tyrosyl phosphorylated proteins and PI 3-kinase in anti-IRS-1 immunoprecipitates from the liver of control and 
glucagon-treated rats. The liver proteins were extracted and processed in extraction buffer B as described in section 2, and then incubated at 4°C 
with anti-IRS antibody and Protein A-Sepharose 6MB. Immunoprecipitated proteins were analyzed by immunoblotting with anti-phosphotyrosine 
(panel B) and anti-PI 3-kinase (85 kDa subunit) (panel C) antibodies and [~25I]protein A and subjected to autoradiography. The data shown are 
representative of several independent experiments. (D) Insulin receptor and IRS-1 protein levels and tyrosine phosphorylation in the liver of control 
and glucagon-treated rats. Scanning densitometry of autoradiograms was performed on 8 experiments o determine the insulin receptor and IRS-1 
concentration, 9 experiments for the tyrosine phosphorylation levels of both proteins and 6 experiments for PI 3-kinase associated with IRS-1. The 
data are expressed as the mean + S.E.M. and are normalized per protein. *, significant differences at least at P < 0.05. 
gation the supernatant was used for immunoprecipitation with anti- 
IRS-1 antibody. 
2.2.2. Protein analysis by immunoblotting. The samples were 
treated with Laemmli sample buffer [17] with 100 mM DTT and heated 
in a boiling water bath for 4 min. For total extracts, imilar size aliquots 
of sample (150/tg of protein) were subjected to SDS-PAGE (6% Tris 
acrylamide) in a Bio-Rad miniature slab gel apparatus. Electrotransfer 
of proteins from the gel to the nitrocellulose membrane was performed 
for 2 h at 120 V (constant) in the Bio-Rad miniature transfer apparatus 
(Mini-Protean) as described by Towbin et al. [18] but with 0.02% SDS 
added to the transfer buffer to enhance the elution of high molecular 
mass proteins. Non-specific protein binding to the nitrocellulose was 
reduced by preincubating the filter overnight at 4°C in blocking buffer 
(3% BSA, 10 mM Tris, 150 mM NaC1, and 0.02% Tween 20). The 
prestained molecular weight standards used included myosin (205 
kDa), fl galactosidase (116 kDa), bovine serum albumin (80 kDa), and 
ovalbumin (49.5 kDa). 
The nitrocellulose blot was incubated with anti-phosphotyrosine a - 
tibodies, anti-insulin receptor antibodies, anti-IRS-1 antibodies or anti- 
PI 3-kinase antibodies diluted in blocking buffer for 4 h at 22°C and 
washed for 60 min with the blocking buffer without BSA. The blots 
were then incubated with 2 mCi of [1251]protein A (30 mCi/mg) in 10 ml 
of blocking buffer for 1 h at 22°C and washed again as described above 
for 2 h. ~25I-Protein A bound to the antibodies was detected by autora- 
diography using preflashed Kodak XAR film with Cronex Lightning 
Plus intensifying screens at -70°C for 12~,8 h. Band intensities were 
quantitated by optical densitometry (Molecular Dynamics) of the de- 
veloped autoradiogram. 
2.3. Other 
Protein determination was performed by the Bradford dye method 
[19] using the Bio-Rad reagent and BSA as the standard. 
2.4. Statistics 
Experiments were always performed using samples from glucagon- 
treated animals in parallel with a control group. Comparisons were 
made using student's paired and unpaired t test as appropriate. The 
level of significance employed was P < 0.05. 
3. Results and discussion 
In the present study, we have evaluated the effect of glucagon 
on insulin receptor and IRS-1 phosphorylat ion and on the 
association of PI 3-kinase with 1RS-1 in the liver and muscle 
of rats treated with glucagon. Acute glucagon-treatment had no 
effect on the insulin receptor and IRS-1 protein levels in liver 
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Fig. 2. Insulin-stimulated yrosine phosphorylation in the intact muscle of rats treated with glucagon. Rats were anesthetized, the abdominal wall 
incised to expose viscera. Normal saline (lanes 1,3) or 10-SM insulin (lanes 2,4) was infused into the portal vein as a bolus injection and 90 seconds 
later the muscle was excised and homogenized in extraction buffer A at 100°C for 5 min as described insection 2.2. After centrifugation aliquots 
containing the same amount of protein were resolved on 6% SDS-polyacrylamide gels, transferred to nitrocellulose, and detected with anti- 
phosphotyrosine antibody (panel A), anti-IRS-1 antibody or anti-insulin receptor antibody and []25I]protein A and then subjected toautoradiography. 
Panels B and C show the immunoblot ftyrosyl phosphorylated proteins and PI 3-kinase in anti-IRS-1 immunoprecipitates from the muscle of control 
and glucagon-treated rats. The muscle proteins were extracted and processed inextraction buffer B as described in the Methods, solubilized and 
incubated at 4°C with anti-IRS antibody and Protein A-Sepharose 6MB. The immunoprecipitated proteins were analyzed by immunoblotting with 
anti-phosphotyrosine (panel B) and anti-PI 3-kinase (85 kDa subunit) (panel C) antibodies and []25I]protein A and then subjected toautoradiography. 
The data shown are representative of several independent experiments. (D) Insulin receptor and IRS-1 protein levels and tyrosine phosphorylation 
in muscle of glucagon-treated rats. Scanning densitometry was performed on autoradiograms from 8 experiments with insulin receptor concentration, 
12 experiments with IRS-1 protein levels, 8experiments forthe tyrosine phosphorylation f both proteins and 6 experiments forPI 3-kinase associated 
with IRS-1. The data are expressed asthe mean + S.E.M. and are normalized per protein. *, differences significant at least at P < 0.05. 
and muscle as determined by immunoblotting with an antibody 
to the C-terminus of the insulin receptor and an antibody to the 
C-terminus of IRS-1, respectively (Figs. 1D and 2D). 
Following insulin infusion into the portal vein, a phosphoty- 
rosine band of 95 kDa, previously identified as the insulin 
receptor fl-subunit, appeared and became prominently 
phosphorylated. The level of phosphorylation f this band was 
reduced to 56 + 7% (P < 0.01) in the liver (Fig. 1A,D) and to 
58 + 7% (P < 0.01) in the muscle (Fig. 2A,D) of rats treated 
with glucagon. This is consistent with previous tudies which 
demonstrated that an increase in the cAMP content of cells 
alters the phosphorylation state and protein kinase activity of 
the insulin receptor [14,15], although such a response is not 
always observed [16]. 
In anti-phosphotyrosine blots of whole tissue extracts, in 
addition to the 95 kDa band seen after insulin injection, a broad 
protein band migrating between 165 and 185 kDa was also 
detectable (Figs. 1A and 2A). This band is known as pp185 and 
IRS-1 is one component of this band [20,21]. The phosphoryl- 
ation of pp185 (kinase activity of insulin receptor toward en- 
dogenous ubstrates) was reduced by 51 + 12% (P < 0.01) in 
the liver (Fig. 1A) and by 62 + 11% (P < 0.01) in the muscle 
(Fig. 2A) of glucagon-treated rats. In order to characterize 
IRS-1 phosphorylation after insulin stimulation, we im- 
munoprecipitated liver and muscle extracts with anti-IRS-1 
antibody and immunoblotted these with anti-phosphotyrosine 
antibody (Figs. 1B and 2B). The results howed that after insu- 
lin stimulation, compared to the controls IRS-1 phosphoryla- 
tion decreased by 57 + 11% (P < 0.01) and 60 + 9% (P < 0.01) 
in the liver and muscle, respectively, of animals treated with 
glucagon (Figs. 1B,D and 2B,D). 
Previous studies [7,8,22-25] have suggested that there is a 
relatively stable, high affinity interaction between 1RS-1 and 
the 85 kDa subunit of PI 3-kinase, such that both proteins are 
co-precipitated byantibodies to either protein. In samples from 
muscle and liver previously immunoprecipitated with anti-IRS- 
1 antibody and subsequently incubated with antibodies directed 
against he 85 kDa subunit of P! 3-kinase, there was little 
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detectable PI 3-kinase immunoreactivity in the basal state in 
either the normal or glucagon-treated animals (Figs. 1C and 
2C). After stimulation with insulin, a band with the expected 
molecular weight of the regulatory subunit of PI 3-kinase (85 
kDa) was present in anti-IRS-1 antibody immunoprecipitates 
from the muscle (Fig. 2C) and liver (Fig. 1C) of both groups 
of rats, which was consistent with the formation of a stable 
association between IRS-1 and PI 3-kinase. However, the 
amount of PI 3-kinase associated with IRS-1 was reduced by 
55 + 9% (P < 0.01) in liver and by 57 + 8% (P < 0.01) in the 
muscle of glucagon-treated rats, demonstrating less association 
between IRS-1 and PI 3-kinase. Recent evidence from various 
sources suggests that the IRS-1/PI 3-kinase pathway may be 
linked to the activation of glucose transport [26-28]. Interest- 
ingly, Sato et al. [29] demonstrated that glucagon inhibits acti- 
vation of glucose transport by insulin in rat adipocytes, mainly 
through a postbinding process. Based on these results, it seems 
reasonable to speculate that a reduction in the interaction and 
activity of the IRS-I/PI 3-kinase pathway may play a role in the 
reduced glucose uptake induced by glucagon in peripheral tis- 
sues [29]. 
The mechanism(s) by which glucagon alters the three early 
steps in insulin action are not completely underestood but at 
least two possibilities hould be considered. First, it is well 
known that agents which raise intracellular cAMP levels in- 
crease phosphorylation of the insulin receptor at serine and 
threonine residues, reduce insulin-mediated receptor phospho- 
rylation on tyrosine, and inhibit the insulin-dependent tyrosine 
protein kinase activity of the receptor. Thus, cAMP may atten- 
uate insulin action by altering the state of phosphorylation f
the insulin receptor [14-16]. It is not known wether an increase 
in intracellular cAMP also induces a serine phosphorylation in 
IRS-1. However, since insulin receptor kinase activity is re- 
duced, a reduction in IRS-I phosphorylation a d hence in the 
association between IRS-I/PI 3-kinase is also expected. An- 
other possibility arises from recent data showing that an in- 
crease in cellular cAMP through activating protein kinase A 
(PKA) increases the activity of endogenous phosphotyrosine 
phosphatase (PTPase), thus leading to a sequence of 
dephosphorylation [30]. 
Our results may have importance in the crosstalk between 
two major signal pathways. Recently, it was demonstrated that 
hormones, such as glucagon which increase cyclic AMP con- 
centration inhibit the transmission of growth stimulatory sig- 
nals which depend on receptors with tyrosine kinase activity 
and the MAP kinase pathway [31,32], probably by increasing 
Raf-1 phosphorylation at serine-43 in the regulatory domain. 
In the transmission of the insulin signal through its tyrosine 
kinase receptor, the Raf-1 and MAP kinase pathways are 
downstream to IRS-1. The present study has demonstrated that 
glucagon, probably acting through cyclic AMP and PKA, in- 
hibits insulin signal transmission at the three early steps, i.e. 
insulin receptor and IRS-1 phosphorylation a d the interaction 
between IRS-1 and PI 3-kinase. Thus, at least for insulin signal 
transmission, the inhibition induced by hormones that increase 
cyclic AMP levels may also be upstream to Raf-l. 
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